SCHEMBL15545447

SCHEMBL15545447

CCOC(=O)c1cn2cc(Br)sc2n1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
ALDH1A1 P00352 3/20 0.50
POLB P06746 2/20 0.50
HPGD P15428 1/20 0.50
CYP1A2 P05177 2/20 0.45
GAA P10253 1/20 0.45
GABRA2 P47869 6/20 0.43
GABRB2 P47870 6/20 0.43
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
RXFP1 Q9HBX9 2/20 0.42
PKM P14618 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16416828 0.80 KDM4E (0.48) KDM4EALDH1A1POLBHPGDCYP1A2
SCHEMBL15546232 0.77 GABRA2 (0.56) KDM4EALDH1A1POLBHPGDCYP1A2
SCHEMBL15349666 0.77 KDM4E (0.47) KDM4EALDH1A1POLBHPGDCYP1A2
SCHEMBL1999180 0.76 RXFP1 (0.45) KDM4EALDH1A1HPGDMAPTRXFP1
SCHEMBL31210467 0.75 KDM4E (0.49) KDM4EALDH1A1POLBHPGDCYP1A2
SCHEMBL1572425 0.75 ALDH1A1 (0.55) KDM4EALDH1A1POLBHPGDCYP1A2
SCHEMBL15188324 0.74 BAZ2B (0.36) KDM4EALDH1A1POLBHPGDCYP1A2
SCHEMBL1500236 0.73 KDM4E (0.64) KDM4EALDH1A1POLBHPGDCYP1A2
SCHEMBL11953305 0.73 ALDH1A1 (0.45) KDM4EALDH1A1POLBHPGDCYP1A2
SCHEMBL23534234 0.72 KDM4E (0.56) KDM4EALDH1A1POLBHPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028334-A1 N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER WMT AG (DE) 2026-01-29 US disclosed
EP-4504723-A1 N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER WMT AG (DE) 2025-02-12 EP disclosed
CN-118974040-A N- (3- (benzo [ B ] thiophen-2-amido) -phenyl) -2, 3-dihydrobenzo [ B ] [1,4] dioxin-6-amide derivatives and related compounds as lactic acid/ATP production inhibitors for the treatment of cancer 威马特股份公司 2024-11-15 CN disclosed
WO-2023194458-A1 N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER WMT AG (DE) 2023-10-12 WO disclosed
WO-2023194458-A1 N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER WMT AG (DE) 2023-10-12 WO disclosed
US-9617281-B2 Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments LABORATORIES DEL DR. ESTEVE S.A. (ES) 2017-04-11 US disclosed
US-9617281-B2 Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments LABORATORIES DEL DR. ESTEVE S.A. (ES) 2017-04-11 US disclosed
US-9617281-B2 Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments LABORATORIES DEL DR. ESTEVE S.A. (ES) 2017-04-11 US disclosed
EP-2870164-B1 IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS ESTEVE LABOR DR (ES) 2016-09-14 EP disclosed
EP-2870164-B1 IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS ESTEVE LABOR DR (ES) 2016-09-14 EP disclosed
US-20150166574-A1 IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS ESTEVE PHARMACEUTICALS, S.A. (ES) 2015-06-18 US disclosed
US-20150166574-A1 IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS ESTEVE PHARMACEUTICALS, S.A. (ES) 2015-06-18 US disclosed
US-20150166574-A1 IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS ESTEVE PHARMACEUTICALS, S.A. (ES) 2015-06-18 US disclosed
EP-2870164-A1 IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS Laboratorios Del. Dr. Esteve, S.A. (ES) 2015-05-13 EP disclosed
WO-2014006130-A1 IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2014-01-09 WO disclosed
WO-2014006130-A1 IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2014-01-09 WO disclosed
EP-2682395-A1 Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments Laboratorios Del. Dr. Esteve, S.A. (ES) 2014-01-08 EP disclosed
EP-2682395-A1 Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments Laboratorios Del. Dr. Esteve, S.A. (ES) 2014-01-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166574-A1 IMIDAZO[2,1-b]THIAZOLE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS SIGMAR1, TMEM97, ADRB2 KDM4E 4747/4885ALDH1A1 1060/4885POLB 2898/4885
US-20260028334-A1 N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER LDHA, LDHB, SLC6A1 KDM4E 3524/4885ALDH1A1 129/4885POLB 675/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.